Shots:

• The companies collaborated to evaluate the synergistic effects of BI 1701963 (SOS1::pan-KRAS inhibitor) + Lumakras (KRAS G12C inhibitor) in a P-I trial for adult patients with LA or metastatic NSCLC
• The companies will jointly share costs & manage the clinical development for combined therapy. Amgen will sponsor the trial
• The preclinical data showed that the combination may result in increased anti-tumor activity based on complementary mechanisms of targeted oncology agents. BI 1701963 is currently being evaluated in P-I trials as monothx. and in combination with MEK inhibitors- KRASG12C inhibitors- or irinotecan for the treatment of advanced KRAS-mutated cancers

  | Ref: Boehringer Ingelheim | Image: Longevity Technology